Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.59 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.59 |
| ▸ | ESR1 known ✓ | P03372 | 3/20 | 0.57 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.56 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.56 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.56 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.56 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.56 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 0.56 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.56 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.56 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.56 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.56 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.56 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.56 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.56 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.56 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.56 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.56 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981044 | 0.98 | PKM (0.62) | PKMBCHEACHEMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL21225052 | 0.95 | PKM (0.59) | PKMBCHEACHEMAPTALDH1A1 | |
| SCHEMBL8126082 | 0.93 | RARB (0.63) | PKMBCHEACHETP53MAPK1 | |
| SCHEMBL4966805 | 0.90 | TP53 (0.63) | PKMBCHEACHEALDH1A1TP53 | |
| SCHEMBL7165188 | 0.88 | KDM4E (0.68) | PKMBCHEACHEALDH1A1TP53 | |
| SCHEMBL4511317 | 0.86 | DRD2 (0.64) | PKMALDH1A1TP53MAPK1TSHR | |
| Hydrochloric Acid SCHEMBL5412869 | 0.86 | L3MBTL1 (0.68) | BCHEACHEMAPTALDH1A1LTA4H | |
| SCHEMBL6057420 | 0.86 | ESR1 (0.59) | BCHEACHEMAPTALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL10536254 | 0.85 | ESR1 (0.67) | BCHEACHEMAPTALDH1A1TP53 | |
| SCHEMBL631252 | 0.84 | L3MBTL1 (0.70) | BCHEACHEMAPTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404243-B2 | Inhibitors of the Wnt/beta-catenin pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3749640-B1 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | UNIV CALIFORNIA (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240059654-A1 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-22 | — | — | US | disclosed |
| US-11708329-B2 | Inhibitors of the WNT/beta-catenin pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210371384-A1 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| EP-3749640-A1 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | The Regents of the University of California (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019152536-A1 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-08 | — | — | WO | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1585481-A2 | PYRAZOLOPYRIMIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004064721-A2 | A PYRAZOLOPYRIMIDINE COMPOUND AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2004-08-05 | — | — | WO | disclosed |
| US-6177443-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2001-01-23 | — | — | US | disclosed |
| EP-0973778-A1 | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998040385-A1 | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708329-B2 | Inhibitors of the WNT/beta-catenin pathway | CTNNB1, CTNNBL1, CTNND1 | BCHE 3725/4885ACHE 4585/4885ESR1 3860/4885 |
| US-12404243-B2 | Inhibitors of the Wnt/beta-catenin pathway | CTNNB1, CTNNBL1, CTNND1 | BCHE 3725/4885ACHE 4585/4885ESR1 3860/4885 |
| US-20210371384-A1 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | CTNNB1, CTNNBL1, CTNND1 | BCHE 3725/4885ACHE 4585/4885ESR1 3860/4885 |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | KCNJ2, KCNN2, KCNH2 | BCHE 3140/4885ACHE 2389/4885ESR1 4511/4885 |
| US-20240059654-A1 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | CTNNB1, CTNNBL1, CTNND1 | BCHE 3725/4885ACHE 4585/4885ESR1 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.